Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of BAY 2927088 versus standard therapy in HER2-mutant advanced non-small cell lung cancer
CTR20244192Phase 3Active
- Sponsor
- Bayer
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Started Dec 2024; status: active.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244192.